KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

12 May 2020

Company's manufacturing methods and processes reviewed by an independent third-party auditor to ensure the products have the highest-quality ingredients possible.

KND Labs, a manufacturer of hemp-derived ingredients, has earned the accreditation of Active Pharmaceutical Ingredients (API).

KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

The announcement recognizes KND as a certified manufacturer of CBD (cannabidiol) for pharmaceutical applications. On the heels of KND's National Animal Supplement Council (NASC) certification, the Colorado-based manufacturer is one of the only companies in the world with both certifications. In addition, KND recently submitted their UK Novel Foods ingredient application for review by the European Union.

Earlier this month, the DEA announced the de-scheduling of GW Pharmaceuticals' Epidiolex, which has marijuana-derived CBD. Although KND ingredients are hemp-derived, which has long been considered a de-scheduled substance, it is a significant move towards CBD being widely recognized for pharmaceutical use.

"We are thrilled to receive our API certification and the ability to propel CBD into the pharmaceutical space," said Nich Wilson, president of KND.

KND formulates heavily certified products, including its pure, plant-based CBD ingredients and customizable blends, allowing the pharmaceutical industry to gain confidence in CBD ingredients. The company claims its formulations adhere to the highest quality standards for manufacturing and testing to achieve the safest product available on the market. Currently, KND produces 1.2 billion doses per month, with the ability to increase capacity with new partners.

KND underwent a rigorous review of all manufacturing methods and processes by an independent third-party auditor to ensure the products have the highest-quality ingredients possible to provide reliability and consistency for finished goods to be used within pharmaceuticals.

"Our team is proud to be at the forefront of certification, compliance and purity in our manufacturing process," said Haakon Currie, compliance manager at KND. "It has always been our goal to distribute high-quality, plant-based CBD ingredients around the world."

In addition to being API and NASC certified, KND is cGMP 111 and 117 certified, ISO 9001:2015 certified and EFfCI (cosmetic euGMP) certified, as well as Kosher certified.

In its two modern facilities in Lakewood, Colorado, and Arvada, Colorado, KND extracts quality, finished bulk ingredients for brands and manufacturers. The company is able to control the manufacturing process of its hemp-derived ingredients by extracting specific cannabinoid profiles to produce CBD, CBG and the isolation of other hemp-derived cannabinoids in a variety of forms including powdered isolate, distillate oils and liquid or powder water-soluble products.

Related categories

Related tags

Market News Certification

Related news

Can the industry really claim it's 'business as usual'?

Can the industry really claim it's 'business as usual'?

19 May 2020

ChargePoint Technology's Chief Commercial Officer says "yes" it can.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

19 May 2020

The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Pharmapack expert recommends holistic approach to sustainability

Pharmapack expert recommends holistic approach to sustainability

18 May 2020

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

12 May 2020

CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Demand for immunity products to be sustained long-term says SIRIO

Demand for immunity products to be sustained long-term says SIRIO

11 May 2020

Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.

Read more 
AbbVie completes Allergan acquisition

AbbVie completes Allergan acquisition

11 May 2020

Creates biopharmaceutical company with leadership positions in immunology, hematologic oncology, neuroscience, and Allergan aesthetics.

Read more